Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada

References

• GeertsWHBergqvistDPineoGFPrevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).Chest20081336 Suppl381s453s18574271
   PubMed Web of Science ®Google Scholar
• Markovic-DenicLZivkovicKLesicABumbasirevicVDubljanin-RaspopovicEBumbasirevicMRisk factors and distribution of symptomatic venous thromboembolism in total hip and knee replacements: prospective studyIn Orthop201236612991305
   Google Scholar
• Falck-YtterYFrancisCWJohansonNAPrevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Supple278S325S22315265
   PubMed Web of Science ®Google Scholar
• JamesonSSBottleAMalviyaAMullerSDReedMRThe impact of national guidelines for the prophylaxis of venous thromboembolism on the complications of arthroplasty of the lower limbJ Bone Joint Surg Br201092112312920044690
   PubMedGoogle Scholar
• GuyattGHAklEACrowtherMGuttermanDDSchuunemannHJExecutive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Suppl7s47s22315257
   PubMed Web of Science ®Google Scholar
• DahlOEGudmundsenTEPrippAHAanesenJJClinical venous thromboembolism following joint surgery: effect of extended thromboprophylaxis on its annual frequency and postoperative pattern over 22 yearsClin Appl Thromb Hemost201420211712324113492
   PubMed Web of Science ®Google Scholar
• ErikssonBIDahlOERosencherNOral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trialJ Thromb Haemost20075112178218517764540
   PubMed Web of Science ®Google Scholar
• WarwickDFriedmanRJAgnelliGInsufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic RegistryJ Bone Joint Surg Br200789679980717613508
   PubMedGoogle Scholar
• WarwickDPrevention of venous thromboembolism in total knee and hip replacementCirculation2012125172151215522547755
   PubMed Web of Science ®Google Scholar
• LiebermanJRHeckmannNVenous thromboembolism prophylaxis in total hip arthroplasty and total knee arthroplasty patients: from guidelines to practiceJ Am Acad Orthop Surg2017251278979829176502
   PubMed Web of Science ®Google Scholar
• GuyattGWalterSNormanGMeasuring change over time: assessing the usefulness of evaluative instrumentsJ Chronic Dis19874021711783818871
   PubMedGoogle Scholar
• HullRDPineoGFFrancisCLow-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs. in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial InvestigatorsArch Intern Med2000160142208221510904465
   PubMedGoogle Scholar
• MuntzJThromboprophylaxis in orthopedic surgery: how long is long enough?Am J Orthop (Belle Mead, NJ)200938839440119809604
   PubMedGoogle Scholar
• FriedmanRJGallusAGil-GarayEFitzGeraldGCushnerFPractice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty–insights from the Multinational Global Orthopaedic Registry (GLORY)Am J Orthop (Belle Mead, NJ)2010399 Suppl142121290027
   PubMedGoogle Scholar
• WilkeTPatient preferences for an oral anticoagulant after major orthopedic surgery: results of a german surveyPatient200921394922273058
   PubMedGoogle Scholar
• FisherWDImpact of venous thromboembolism on clinical management and therapy after hip and knee arthroplastyCan J Surg201154534435121774881
   PubMed Web of Science ®Google Scholar
• GombarCHorvathGGalityHSisakKTothKComparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplastyArch Orthop Trauma Surg2014134444945724488447
   PubMed Web of Science ®Google Scholar
• FanolaCLCurrent and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatranVasc Health Risk Manag20151127128226064057
   PubMedGoogle Scholar
• ErikssonBIDahlOEHuoMHOral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trialThromb Haemost2011105472172921225098
   PubMed Web of Science ®Google Scholar
• GinsbergJSDavidsonBLCompPCOral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgeryJ Arthroplasty200924119
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Canada LtdPradaxa product monograph. Dabigatran etexilate capsules2016 Available from: https://www.boehringer-ingelheim.ca/sites/ca/files/documents/pradaxapmen.pdfAccessed June 15, 2017
   Google Scholar
• Sanofi-aventis Canada IncLovenox product monograph. Enoxaparin sodium solution for injection2013 Available from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.592.7577&rep=rep1&type=pdfAccessed June 15, 2017
   Google Scholar
• The European Agency for the Evaluation of Medicinal ProductsGuideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk2007 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143764.pdfAccessed June 15, 2017
   Google Scholar
• JanuelJMChenGRuffieuxCSymptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic reviewJAMA2012307329430322253396
   PubMed Web of Science ®Google Scholar
• FriedmanRJDahlOERosencherNDabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trialsThromb Res2010126317518220434759
   PubMed Web of Science ®Google Scholar
• OzlerTUlucayCOnalAAltintasFComparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacementActa Orthop Traumat Turc2015493255259
   PubMed Web of Science ®Google Scholar
• SubramanianPKantharubanSShilstonSPearceOJA 12 month review of a modified protocol using low dose Dabigatran Etexilate in postoperative thromboembolic prophylaxis in joint replacement surgeryThromb J20121011422916689
   PubMedGoogle Scholar
• WurnigCClemensARauscherHSafety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgeryThromb J2015133726612979
   PubMedGoogle Scholar
• PedersenABMehnertFSorensenHTEmmeluthCOvergaardSJohnsenSPThe risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: a 15-year retrospective cohort study of routine clinical practiceBone Joint J201496-b447948524692614
   PubMed Web of Science ®Google Scholar
• ForsterRStewartMAnticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repairCochrane Database Syst Rev20163CD00417927027384
   PubMedGoogle Scholar
• ErikssonBIDahlOERosencherNOral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trialsThromb J2015133626578849
   PubMedGoogle Scholar
• RosencherNSamamaCMFeuringMDabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical settingThromb J201614827042163
   PubMedGoogle Scholar
• BlochBVPatelVBestAJThromboprophylaxis with dabigatran leads to an increased incidence of wound leakage and an increased length of stay after total joint replacementBone Joint J201496-b1122126
   PubMedGoogle Scholar